Takeda to pay Bayer $155 million over hemophilia drug

Jurors in the federal court in Wilmington, Delaware, reached their verdict on the seventh day of a trial after rejecting Baxalta’s argument that the June 2016 patent on the treatment, Adynovate, was invalid.

U.S: A U.S. jury has ordered Takeda Pharmaceutical Co’s Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta haemophilia treatment, court records made public on Tuesday show.

Jurors in the federal court in Wilmington, Delaware, reached their verdict on the seventh day of a trial after rejecting Baxalta’s argument that the June 2016 patent on the treatment, Adynovate, was invalid.

Bayer said the infringement arose from Baxalta’s exclusive license agreement with Nektar Therapeutics, a San Francisco-based company that had done research with Bayer and knew about the patent, including through litigation in Germany.

The award covered the period from June 14, 2016, to Nov. 30, 2018. Jurors applied a royalty rate of 17.78 per cent to a royalty base of $872.84 million to arrive at the damages award.

Bayer is based in Leverkusen, Germany, with U.S. offices in Whippany, New Jersey.